U2AF1 and myeloproliferative neoplasm: U2AF1 mutation frequencies in these studies were 5–21.7% in MDS, 3.4–12.3% in AML, 0–8% in CML, 1.2–8% in MPN, and 5.7–14.5% in MDS/MPN overlap patients.